RNA Outsourcing Videos

  1. How Outsourcing mRNA Development Has Evolved Since COVID 2/10/2025

    Advancing RNA panelists Alex Aust, Qian Ruan, and Andy Geal share their thoughts on the ways in which outsourcing firms are approaching mRNA development today, as well as why outsourcing — as opposed to building a GMP facility — remains critical for (x)RNA biotechs today.

  2. Customized mRNA Processing For Improved Therapy Development And Manufacturing 2/13/2025

    Optimize mRNA development by learning key strategies for process refinement, critical component identification, and in-process analytics to enhance therapeutic production.

  3. The Conjugation Conundrum: The Realities Of Conjugated LNP Manufacturing 2/24/2026

    In this Advancing RNA Live clip, CMC Consultant Sujit Jain explains the numerous ways that adding targeting ligands “stress tests” the standard LNP manufacturing platform, as well as outlines which capabilities are most important for companies to consider when selecting an outsourcing partner for their active delivery strategies.

  4. mRNA's Impact On Cost And Capacity To Surge Biopharma Production 5/22/2023

    TFF Pharmaceuticals’ Kayla Hannon and University of Sheffield’s Dr. Zoltán Kis discuss the cost and capacity implications of therapeutic demand surges in this Surge Manufacturing for Biopharma Resilience segment.

  5. Optimizing Viability And Standardization For Clinical Excellence 10/2/2024

    Explore how IntegriCell™ delivers high-quality, manufacture-ready cryopreserved leukopaks, vital for consistent and reliable cell therapy production.

  6. The Synergistic Role Of Drug Safety In Clinical Trial Operations 4/25/2024

    Delve into the significance of adept interpersonal leadership within your drug safety program, shedding light on the operational and financial benefits that stem from fostering a collaborative environment.

  7. Regulatory And Biosafety Testing Expertise 3/31/2026

    Advancing biologics requires confidence in safety, quality, and compliance. Learn how integrated analytical and biosafety testing, backed by decades of expertise, helps reduce risk.

  8. Addressing mRNA's Scalability And Supply Challenges 3/14/2022

    Tune in as Roberta Duncan, VP of the mRNA program at Seqirus; Duke Human Vaccine Institute Associate Director of Upstream and Downstream Process Development Jason Dickens, Ph.D.; and Jin Zhou, Executive Director of Process Development for mRNA and Protein Biologics at Ultragenyx share supply chain and manufacturing capacity constraints in the face of the urgency to address COVID-19. This is an excerpt from the Bioprocess Online Live event - mRNA Manufacturing: Bright Future, Big Challenges.

  9. mRNA Capabilities 3/4/2025

    Discover how our advanced capabilities in Hopkinton, MA, are overcoming the challenges of large-scale RNA therapeutic manufacturing, enabling the efficient production of complex srRNA and mRNA therapies.

  10. Recipharm Advanced Bio Capabilities Update September 2026: mRNA 10/8/2026

    RNA therapeutics are reshaping disease treatment, but success requires coordinated expertise in plasmid production, RNA synthesis, formulation, analytics, and manufacturing.